This analysis examines the current position and future outlook for Schering AG in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-7 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information
Reasons to Purchase
Evaluate the level of risk involved in Schering’s forecast dependence on current pipeline products for 16.7% of sales in 2010
Benchmark Schering AG’s performance against key rivals in the ethical pharmaceutical sector
Evaluate the importance key threats to Schering’s women’s health franchise to the company’s performance over the forecast period
